Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Goals, Safety, And Effectiveness - NAPLEX

  1. A 40-year-old woman (62 kg, 168 cm) presents with nausea, tremor, and confusion 5 days after her psychiatrist increased lithium carbonate from 300 mg twice daily to 600 mg twice daily. Current medications: lithium carbonate 600 mg twice daily, ibuprofen 600 mg three times daily for back pain (started 1 week ago), sertraline 100 mg daily. PMH: bipolar disorder. Labs: lithium level 1.9 mEq/L (high; typical maintenance 0.6–1.2), SCr 1.3 mg/dL (baseline 0.8). Allergies: none. Which drug-related problem needs immediate attention?
    Answer: Recognize probable lithium toxicity; stop NSAID use, hold lithium, and arrange urgent medical evaluation with repeat levels and renal monitoring Person-centered assessment requires recognizing drug-induced toxicity from pharmacokinetic interactions, particularly with narrow therapeutic index drugs. The key patient-specific factors are lithium toxicity symptoms (nausea, tremor, confusion) with elevated lithium level (1.9 mEq/L) and increased creatinine, precipitated by NSAID use which reduces renal lithium clearance. Recognizing toxicity and stopping the NSAID while holding lithium pending urgent evaluation (choice B) is critical to prevent progression to severe toxicity including seizures or coma. Continuing current therapy (A) ignores clear toxicity signs. Increasing lithium (C) would worsen potentially life-threatening toxicity. Changing antidepressants (D) doesn't address the primary lithium-NSAID interaction causing toxicity. The clinical pearl is that NSAIDs significantly increase lithium levels by reducing renal clearance; always screen for NSAID use (prescription and OTC) in lithium-treated patients and educate about avoiding NSAIDs or using alternatives like acetaminophen when possible.
  2. A 58-year-old man (92 kg, 178 cm) presents for medication reconciliation after hospital discharge for an acute coronary syndrome with drug-eluting stent placement 10 days ago. Current medications: aspirin 81 mg daily, clopidogrel 75 mg daily, omeprazole 20 mg daily, atorvastatin 80 mg nightly, metoprolol succinate 50 mg daily, lisinopril 10 mg daily, nitroglycerin 0.4 mg SL as needed. PMH: GERD, HTN, HLD. Labs: SCr 1.0 mg/dL; AST/ALT within normal limits. Allergies: none. Which drug-related problem needs immediate attention?
    Answer: Switch omeprazole to pantoprazole 40 mg daily to reduce the interaction risk with clopidogrel Person-centered assessment requires evaluating drug interactions that could compromise therapeutic outcomes, particularly in high-risk cardiovascular patients. The key patient-specific factor is the concurrent use of omeprazole with clopidogrel, which can reduce clopidogrel's antiplatelet effect through CYP2C19 inhibition, potentially increasing the risk of stent thrombosis. Switching to pantoprazole (choice B) is the best option because pantoprazole has minimal CYP2C19 inhibition and maintains gastroprotection while preserving clopidogrel's efficacy. Continuing the current regimen (A) ignores a clinically significant interaction that could lead to treatment failure. Discontinuing aspirin (C) would eliminate dual antiplatelet therapy, which is essential for at least 12 months after drug-eluting stent placement. Reducing clopidogrel dose (D) would further compromise antiplatelet effect without addressing the interaction. The clinical pearl is to always screen for CYP-mediated interactions with antiplatelet agents, particularly PPIs with clopidogrel, and select alternatives that minimize interaction risk while maintaining therapeutic benefit.
  3. A 63-year-old man (78 kg) with COPD is started on azithromycin for community-acquired pneumonia. PMH: COPD, prolonged QT history. Current meds: tiotropium inhaled daily, albuterol inhaled PRN, citalopram 40 mg PO daily. Baseline ECG shows QTc 510 ms. Labs: K 3.2 mEq/L (low), Mg 1.6 mg/dL (low), SCr 0.9 mg/dL. Allergies: none. What is the most important safety consideration for this therapy?
    Answer: Address QT-prolongation risk by correcting electrolytes and avoiding/adjusting QT-prolonging agents (e.g., reconsider azithromycin and/or reduce citalopram) Person-centered assessment and treatment planning in pneumonia therapy require evaluating for drug-induced QT prolongation risks, especially in patients with baseline prolongation. The key patient-specific factor is the history of prolonged QTc, concurrent citalopram use, and electrolyte imbalances, which heighten arrhythmia risk with azithromycin. Addressing QT-prolongation by correcting electrolytes and adjusting QT-prolonging agents is the best choice for safety, as it mitigates torsades de pointes risk. Continuing azithromycin and citalopram without adjustment ignores the interaction; holding albuterol is unnecessary as it doesn't affect QT; adding diphenhydramine is irrelevant for rash prevention. In patients with QT risks, select antibiotics with lower QT potential like beta-lactams. Monitor ECG and electrolytes routinely in high-risk polypharmacy scenarios.
  4. A 62-year-old man (91 kg) with gout presents for follow-up after starting allopurinol 4 weeks ago. PMH: gout, CKD stage 3b, HTN. Meds: allopurinol 300 mg PO daily, colchicine 0.6 mg PO daily (prophylaxis), losartan 50 mg PO daily. Labs: SCr 2.1 mg/dL (eGFR 32 mL/min/1.73 m2^2), uric acid 5.8 mg/dL, CBC WNL, LFTs WNL. He reports no flares and mild diarrhea. Which parameter should be closely monitored for effectiveness?
    Answer: Serum uric acid Person-centered assessment and treatment planning for gout involve monitoring uric acid to assess urate-lowering therapy effectiveness. The key patient-specific factor is allopurinol initiation in CKD, where uric acid levels guide dose adjustments. Serum uric acid should be closely monitored for effectiveness, targeting <6 mg/dL to prevent flares. INR is for anticoagulation; troponin for cardiac events; amylase for pancreatitis. In gout management, titrate allopurinol based on uric acid and eGFR. Use prophylaxis like colchicine during initiation to minimize flares.
  5. A 26-year-old woman (64 kg) presents for therapy initiation for acne vulgaris. PMH: none. Meds: combined oral contraceptive daily. She is not pregnant and uses reliable contraception. Allergies: none. She asks about starting isotretinoin. What is the most important safety consideration for this therapy?
    Answer: Ensure enrollment in a pregnancy prevention program and confirm negative pregnancy testing before and during therapy due to teratogenicity Person-centered assessment and treatment planning for acne with isotretinoin emphasize teratogenicity prevention in females of childbearing potential. The key patient-specific factor is reproductive age, requiring strict pregnancy prevention measures. Ensuring enrollment in a prevention program with testing is the best choice for safety. Avoiding dairy is unnecessary; co-administering tetracycline increases pseudotumor risk; INR monitoring is not routine. In isotretinoin therapy, use iPLEDGE program mandates. Counsel on dual contraception and monthly testing.
  6. A 45-year-old woman (70 kg) presents with dysuria and urinary frequency for 2 days. UA is consistent with uncomplicated cystitis; urine culture pending. PMH: none. Meds: ethinyl estradiol/levonorgestrel 1 tablet PO daily. Labs: SCr 0.8 mg/dL (eGFR 105 mL/min/1.73 m2^2). Allergies: anaphylaxis to trimethoprim-sulfamethoxazole. Not pregnant. Which treatment plan best addresses the patient's clinical needs?
    Answer: Start nitrofurantoin monohydrate/macrocrystals 100 mg PO twice daily for 5 days Person-centered assessment and treatment planning for urinary tract infections involve selecting antibiotics based on allergy history, renal function, and guidelines for uncomplicated cases. The key patient-specific factor is the anaphylactic allergy to trimethoprim-sulfamethoxazole, necessitating an alternative agent with good efficacy for cystitis. Nitrofurantoin is the best choice as it is recommended for uncomplicated cystitis in women with normal renal function and avoids the allergy risk. Ciprofloxacin is reserved for complicated cases or resistance; trimethoprim-sulfamethoxazole is contraindicated due to allergy; amoxicillin/clavulanate is not first-line for short-duration therapy in uncomplicated cystitis. For UTI management, consider local resistance patterns and patient allergies when selecting therapy. Emphasize hydration and follow-up cultures to ensure resolution and prevent recurrence.
  7. A 52-year-old woman (82 kg, 165 cm) is seen for monitoring and follow-up of hypertension. PMH: HTN, gout. Meds: hydrochlorothiazide 25 mg PO daily, amlodipine 10 mg PO daily, allopurinol 300 mg PO daily. BP today 152/94 mmHg (average home BP similar). Labs: SCr 0.9 mg/dL, K 3.4 mEq/L (low). Allergies: none. How should the patient's medication regimen be adjusted?
    Answer: Add lisinopril 10 mg PO daily and recheck potassium and SCr in 1–2 weeks Person-centered assessment and treatment planning for hypertension involve stepwise addition of agents while monitoring electrolytes and renal function, considering comorbidities like gout. The key patient-specific factor is uncontrolled blood pressure on current therapy and low potassium, where adding an ACE inhibitor addresses both without worsening gout. Adding lisinopril with monitoring is the best choice for effectiveness and safety, as it provides additive BP control and potassium-sparing effects. Increasing hydrochlorothiazide may worsen hypokalemia and gout; switching to verapamil ignores gout risk; stopping hydrochlorothiazide for indomethacin is inappropriate as NSAIDs can elevate BP. In hypertension with gout, prefer non-thiazide options or add agents like ACE inhibitors. Regularly assess electrolytes and renal function post-adjustment to ensure safety.
  8. A 61-year-old woman (68 kg) presents for therapy initiation after a DEXA scan shows osteoporosis (T-score -2.7 at femoral neck). PMH: GERD, CKD stage 3a. Meds: calcium carbonate 500 mg elemental daily, vitamin D3 1,000 units daily, pantoprazole 40 mg daily. Labs: SCr 1.1 mg/dL (eGFR 52 mL/min/1.73 m2^2), Ca 9.2 mg/dL, 25-OH vitamin D 28 ng/mL. Allergies: none; she can sit upright for 30 minutes and has no esophageal strictures. Which treatment plan best addresses the patient's clinical needs?
    Answer: Start alendronate 70 mg PO once weekly with administration counseling Person-centered assessment and treatment planning for osteoporosis prioritize agents suitable for renal function and administration feasibility. The key patient-specific factor is CKD stage 3a with GERD, where oral bisphosphonates require proper administration to minimize esophageal risks. Starting alendronate weekly with counseling is the best choice for efficacy and safety, as it's first-line with once-weekly dosing improving adherence. Calcitonin is not first-line for long-term therapy; daily alendronate increases GI risk; IV ibandronate weekly is excessive and not standard. In osteoporosis with CKD, adjust dosing for eGFR and ensure vitamin D optimization. Counsel on upright posture post-dose to prevent esophagitis.
  9. A 34-year-old woman (68 kg, 167 cm) presents for therapy initiation after a new diagnosis of moderate persistent asthma. She reports symptoms 4 days/week and nighttime awakenings 2 times/month; uses albuterol most days. Current medications: albuterol HFA 2 puffs every 4–6 hours as needed, cetirizine 10 mg daily. PMH: allergic rhinitis. Labs: not applicable. Allergies: none; not pregnant. Which treatment plan best addresses the patient's clinical needs?
    Answer: Start low-dose inhaled corticosteroid-formoterol as maintenance and reliever therapy, with inhaler technique counseling Person-centered assessment for asthma requires matching controller therapy intensity to disease severity while considering patient preferences and adherence factors. The key patient-specific factor is moderate persistent asthma with frequent symptoms (4 days/week) and reliever use, indicating inadequate control requiring anti-inflammatory therapy. Starting low-dose ICS-formoterol as maintenance and reliever therapy (choice B) provides both anti-inflammatory control and as-needed relief with a single inhaler, improving adherence and outcomes. Montelukast alone (A) is less effective than ICS for persistent asthma and insufficient for moderate disease. Tiotropium monotherapy (C) is not first-line for asthma and discontinuing albuterol removes rescue capability. Long-term oral steroids (D) cause serious adverse effects and are never appropriate for routine asthma control. The clinical pearl is that ICS-formoterol combination as both maintenance and reliever therapy (SMART approach) simplifies regimens, improves adherence, and reduces exacerbations compared to traditional stepped care in moderate persistent asthma.
  10. A 29-year-old woman (62 kg) with epilepsy calls stating she started a new medication 1 week ago and now has a diffuse rash with facial swelling and fever. PMH: focal seizures. Meds: lamotrigine titration currently 50 mg PO twice daily, levetiracetam 1,000 mg PO twice daily. Labs: AST/ALT mildly elevated; SCr WNL. Allergies: none known. Which drug-related problem needs immediate attention?
    Answer: Lamotrigine hypersensitivity reaction; stop lamotrigine immediately and refer for urgent evaluation Person-centered assessment and treatment planning in epilepsy require prompt recognition of serious adverse drug reactions like hypersensitivity. The key patient-specific factor is the timing of rash onset with lamotrigine titration, suggesting a potentially severe reaction like Stevens-Johnson syndrome. Stopping lamotrigine and referring for evaluation is the best choice for safety, as immediate discontinuation prevents progression. Levetiracetam is not typically associated with SJS; continuing lamotrigine with hydrocortisone risks escalation; facial swelling is unrelated to opioid allergy. In anticonvulsant therapy, educate on rash warning signs and titrate slowly. Use HLA testing in at-risk populations to guide safer prescribing.
  11. A 33-year-old woman (58 kg) is 10 weeks pregnant and requests help for nausea and vomiting. PMH: none. Meds: prenatal vitamin daily. Labs: not applicable. Allergies: none. Symptoms are affecting her ability to work but she is tolerating some oral intake. Which treatment plan best addresses the patient's clinical needs?
    Answer: Start pyridoxine (vitamin B6) 25 mg PO three times daily plus doxylamine 12.5 mg PO at bedtime (or divided dosing) as needed Person-centered assessment and treatment planning for nausea in pregnancy prioritize safe, evidence-based options avoiding teratogens. The key patient-specific factor is first-trimester pregnancy with moderate symptoms, requiring non-teratogenic therapy. Pyridoxine plus doxylamine is the best choice as it's first-line and safe in pregnancy. Isotretinoin is highly teratogenic; bismuth subsalicylate risks salicylate exposure; warfarin is contraindicated in pregnancy. In hyperemesis gravidarum, escalate based on severity using ACOG guidelines. Counsel on dietary strategies alongside pharmacotherapy for symptom relief.
  12. A 57-year-old woman (69 kg) with major depressive disorder reports missing doses of sertraline due to nausea and forgetfulness. PMH: depression, GERD. Meds: sertraline 100 mg PO every morning, pantoprazole 40 mg PO daily. Labs: not applicable. Allergies: none. She is motivated to feel better but wants fewer side effects. What is the best approach to improve patient adherence?
    Answer: Recommend taking sertraline with food and using a daily reminder tool (e.g., phone alarm/pillbox); consider dose timing adjustment if nausea persists Person-centered assessment and treatment planning for depression focus on improving adherence through side effect management and tools. The key patient-specific factor is nausea and forgetfulness affecting sertraline compliance. Recommending administration with food and reminders is the best choice for adherence without abrupt changes. Abrupt stopping risks withdrawal; doubling doses causes toxicity; switching to phenelzine requires washout and diet restrictions. In antidepressant therapy, use motivational interviewing for adherence. Adjust timing or formulations to minimize GI effects.
  13. A 55-year-old man (83 kg) is being treated for benign prostatic hyperplasia (BPH). PMH: BPH, cataracts scheduled for surgery in 1 month. Meds: tamsulosin 0.4 mg PO daily started 2 weeks ago, sildenafil 50 mg PO PRN. Vitals: BP 118/70 mmHg. Labs: SCr 1.0 mg/dL. Allergies: none. What is the most important safety consideration for this therapy?
    Answer: Tamsulosin may cause intraoperative floppy iris syndrome; ensure ophthalmologist is informed before cataract surgery Person-centered assessment and treatment planning require evaluating a patient's full medical history, including upcoming procedures and medication risks, to ensure safe and effective therapy. Here, the key patient-specific factor is the scheduled cataract surgery in a patient recently started on tamsulosin, which increases the risk of intraoperative complications. The best choice is A because informing the ophthalmologist about tamsulosin use allows for precautionary measures during surgery to mitigate intraoperative floppy iris syndrome (IFIS), prioritizing patient safety and procedural effectiveness. Choice B is incorrect as tamsulosin is not contraindicated with PDE5 inhibitors like sildenafil; they may cause additive hypotension but can be managed with monitoring rather than permanent discontinuation. Choices C and D are less optimal; C erroneously suggests INR monitoring which is irrelevant to tamsulosin, and D provides false administration instructions as tamsulosin does not cause hypoglycemia and has no such timing requirements. A transferable clinical pearl is to screen for alpha-blocker use in all patients awaiting cataract surgery, as evidence indicates even short-term exposure heightens IFIS risk. This approach fosters interdisciplinary communication and evidence-based precautions to enhance patient safety across similar scenarios.
  14. A 71-year-old woman (66 kg) presents for medication reconciliation. PMH: hypothyroidism, iron-deficiency anemia, osteoporosis. Meds: levothyroxine 100 mcg PO every morning, ferrous sulfate 325 mg PO twice daily, calcium carbonate 600 mg elemental PO twice daily, alendronate 70 mg PO weekly. Labs: TSH 9.8 mIU/L (high), free T4 low. Allergies: none. She takes all morning medications together with breakfast. Which drug-related problem needs immediate attention?
    Answer: Reduced levothyroxine absorption due to concurrent iron/calcium; separate levothyroxine from cations and administer on empty stomach Person-centered assessment and treatment planning involve tailoring medication regimens to individual patient needs, considering comorbidities, drug interactions, and administration practices to optimize safety and efficacy. In this case, the key patient-specific factor is the concurrent administration of levothyroxine with iron and calcium supplements along with food, which impairs levothyroxine absorption. The best choice is A because separating levothyroxine from cations like iron and calcium, and administering it on an empty stomach, directly addresses the reduced absorption leading to suboptimal hypothyroidism control, enhancing safety and effectiveness. Choice B is incorrect as alendronate does not significantly reduce iron absorption, and stopping it overlooks the primary issue while potentially compromising osteoporosis management. Choices C and D are less optimal; C wrongly attributes hyperthyroidism to ferrous sulfate when the patient is hypothyroid, and D incorrectly states that calcium increases levothyroxine absorption when it actually decreases it. A key clinical pearl is to always review medication timing and food interactions in patients with hypothyroidism, as evidence shows that cations and food can reduce levothyroxine bioavailability by up to 40%. This framework emphasizes patient education on proper administration to prevent subtherapeutic levels and promote adherence in evidence-based practice.
  15. A 69-year-old man (77 kg) is on chronic digoxin for atrial fibrillation rate control. He presents with nausea, decreased appetite, and yellow-tinged vision. PMH: AF, HFrEF. Meds: digoxin 0.25 mg PO daily, furosemide 40 mg PO daily, carvedilol 12.5 mg PO twice daily. Labs: K 2.9 mEq/L (low), SCr 1.4 mg/dL (eGFR 45 mL/min/1.73 m2^2), digoxin level 2.4 ng/mL (high; typical goal 0.5–0.9 for HF). Allergies: none. Which drug-related problem needs immediate attention?
    Answer: Likely digoxin toxicity precipitated by hypokalemia and reduced renal function; hold digoxin and correct electrolytes with close monitoring Person-centered assessment and treatment planning in heart failure require recognizing digoxin toxicity signs and contributing factors. The key patient-specific factor is elevated digoxin level with hypokalemia and reduced eGFR potentiating toxicity. Holding digoxin and correcting electrolytes is the best choice for safety. Carvedilol doesn't cause these symptoms; increasing digoxin worsens toxicity; level is supratherapeutic, not therapeutic. In digoxin use, maintain potassium and monitor levels. Adjust dosing for renal function to prevent accumulation.
  16. A 64-year-old man (88 kg) is hospitalized for acute DVT and is being transitioned to outpatient therapy. PMH: DVT (new), HTN. Meds: lisinopril 20 mg PO daily. Labs: SCr 2.0 mg/dL (eGFR 28 mL/min/1.73 m2^2), AST/ALT WNL, platelets 220,000/mm3^3. Allergies: none. Which treatment plan best addresses the patient's clinical needs?
    Answer: Start unfractionated heparin bridge to warfarin with INR monitoring (goal 2–3) Person-centered assessment and treatment planning for DVT anticoagulation consider renal function for dosing and agent selection. The key patient-specific factor is severe CKD (eGFR 28), where DOACs like rivaroxaban and apixaban require adjustment or avoidance. Starting heparin bridge to warfarin is the best choice for safety in advanced CKD, as warfarin is not renally cleared. Rivaroxaban without adjustment risks accumulation; apixaban is dosed correctly but evidence is limited in eGFR <30; enoxaparin requires renal adjustment. In CKD patients, prefer warfarin or adjusted LMWH for anticoagulation. Monitor INR regularly to achieve therapeutic goals.
  17. A 74-year-old woman (60 kg) is admitted for medication reconciliation after a fall. PMH: atrial fibrillation, CKD stage 3, osteoarthritis, depression. Home meds: warfarin 5 mg PO daily, amiodarone 200 mg PO daily, sertraline 50 mg PO daily, ibuprofen 600 mg PO three times daily, acetaminophen 1,000 mg PO three times daily PRN. Labs: INR 4.6 (goal 2–3), SCr 1.6 mg/dL (eGFR 32 mL/min/1.73 m2^2), AST/ALT WNL. Allergies: none. Which drug-related problem needs immediate attention?
    Answer: Ibuprofen use with warfarin and supratherapeutic INR increases bleeding risk; discontinue ibuprofen and address INR Person-centered assessment and treatment planning for anticoagulation involve identifying drug interactions and monitoring parameters to prevent bleeding or thrombotic events. The key patient-specific factor is the supratherapeutic INR combined with ibuprofen use, which potentiates warfarin's anticoagulant effect and increases bleeding risk in a patient with CKD. Discontinuing ibuprofen and addressing the INR is the best choice for immediate safety, as NSAIDs like ibuprofen are contraindicated with warfarin due to additive bleeding risks. Sertraline with warfarin may increase bleeding but is not the primary issue here and doesn't require immediate cessation; acetaminophen may slightly affect warfarin but increasing dose is inappropriate; amiodarone potentiates rather than reduces warfarin effect, so increasing dose is incorrect. In anticoagulation management, regularly review concurrent medications for interactions and adjust based on INR trends. Prioritize non-NSAID analgesics in patients on warfarin to enhance safety.
  18. A 66-year-old woman (70 kg, 165 cm) reports ankle swelling and flushing since starting amlodipine 10 mg daily 3 weeks ago for hypertension. Current medications: amlodipine 10 mg daily, hydrochlorothiazide 25 mg daily, metformin 1000 mg twice daily, atorvastatin 20 mg nightly. PMH: HTN, type 2 diabetes. Vitals: BP 128/74 mmHg, HR 78 bpm. Labs: SCr 0.9 mg/dL, K 4.2 mEq/L. Allergies: sulfonamide antibiotics (rash). Which treatment plan best addresses the patient's clinical needs?
    Answer: Reduce amlodipine to 5 mg daily and reassess blood pressure and edema in 2–4 weeks Person-centered assessment involves recognizing and managing dose-dependent adverse effects while maintaining therapeutic efficacy. The key patient-specific factor is peripheral edema and flushing from amlodipine, which are common dose-related adverse effects of dihydropyridine calcium channel blockers. Reducing amlodipine to 5 mg daily (choice C) is the best approach because it often resolves edema while maintaining blood pressure control, as evidenced by the patient's current BP of 128/74 mmHg. Adding furosemide (A) treats the symptom without addressing the cause and adds unnecessary medication. Switching to verapamil (B) is inappropriate as non-dihydropyridines have different adverse effect profiles and may cause constipation or bradycardia. Continuing current therapy (D) ignores the patient's quality of life concerns when a simple dose reduction often resolves symptoms. The clinical pearl is that calcium channel blocker-induced edema is dose-dependent and often responds to dose reduction rather than diuretic therapy, maintaining the balance between efficacy and tolerability.
  19. A 50-year-old woman (72 kg) with asthma reports using her albuterol inhaler 4–5 times daily for the past month. PMH: moderate persistent asthma, allergic rhinitis. Current meds: albuterol HFA 2 puffs every 4–6 hours PRN, cetirizine 10 mg PO daily. No controller inhaler. Vitals: no acute distress; peak flow 70% of personal best. Labs: not applicable. Allergies: none. Which treatment plan best addresses the patient's clinical needs?
    Answer: Start low-dose inhaled corticosteroid (e.g., budesonide 180 mcg 2 puffs twice daily) and continue albuterol PRN Person-centered assessment and treatment planning in asthma involve stepping up therapy based on symptom control and guidelines. The key patient-specific factor is frequent albuterol use indicating poor control, requiring addition of a controller. Starting low-dose ICS is the best choice for effectiveness and safety in moderate persistent asthma. Montelukast monotherapy is insufficient; salmeterol monotherapy risks asthma death; indefinite prednisone has significant side effects. In asthma management, follow GINA guidelines for step therapy. Educate on inhaler technique and trigger avoidance for better outcomes.
  20. A 56-year-old man (95 kg) with type 2 diabetes returns for follow-up. Meds: metformin 1,000 mg PO twice daily, empagliflozin 10 mg PO daily. A1c improved from 9.2% to 7.1% in 3 months. He reports frequent urination and increased thirst but no dizziness. Labs: SCr 1.0 mg/dL, eGFR 88 mL/min/1.73 m2^2, Na 138 mEq/L. Allergies: none. What is the most important safety consideration for this therapy?
    Answer: Monitor for genital mycotic infections and volume depletion; counsel on hydration and sick-day management Person-centered assessment and treatment planning in diabetes therapy emphasize monitoring for class-specific adverse effects like those of SGLT2 inhibitors. The key patient-specific factor is symptoms of polyuria and thirst, indicating potential volume depletion from empagliflozin's diuretic effect. Monitoring for genital infections and volume depletion with counseling is the best choice for safety, aligning with SGLT2 inhibitor risks. Agranulocytosis monitoring is for other classes like clozapine; ototoxicity is for aminoglycosides; monthly ECGs are unnecessary for empagliflozin. In SGLT2 therapy, educate on hydration and sick-day rules to prevent dehydration. Assess renal function periodically to guide continuation.

Start this quiz